The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of the body’s own immune cells to recognize and attack melanoma cells. In this webinar, hosted by Samantha Guild, JD, President of AIM at Melanoma, we explore the implications of this newly approved treatment for melanoma care with our guest, Dr. Allison Betof Warner, MD, PhD, a leading expert in TIL therapy.

CLICK on the image below to watch